Clene director granted 2,755 stock options at $4.73

Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock.

Accepted by SEC EDGAR 02/20/2026 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.

Insider Trade Summary

Grant/Award: 2,755 shares

Grant/Award 1 txn

Insider Kiernan Matthew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	stock option	2,755	$0.00	$0.00

Holdings After Transaction: stock option — 2,755 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on February 19, 2026 as an option for 2,755 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Clene Inc. (CLNN) disclose in this Form 4?

Clene Inc. disclosed that director Matthew Kiernan received a grant of stock options for 2,755 shares of common stock. The options were awarded under the company’s Amended 2020 Stock Plan on February 19, 2026 and are part of his equity-based compensation.

How many Clene Inc. (CLNN) shares are covered by Matthew Kiernan’s new stock options?

The stock option grant to director Matthew Kiernan covers 2,755 shares of Clene Inc. common stock. This figure reflects the total number of shares underlying the derivative security reported in the Form 4 insider transaction.

What is the exercise price of Matthew Kiernan’s Clene Inc. (CLNN) stock options?

The options granted to Matthew Kiernan have an exercise price of $4.73 per share. This is the price at which he can purchase Clene Inc. common stock in the future, as specified in the Form 4 footnote disclosure.

When were the new Clene Inc. (CLNN) stock options granted to Matthew Kiernan?

The stock options were granted on February 19, 2026. This grant date is clearly stated in the footnote, which explains the award’s key terms under the Clene Inc. Amended 2020 Stock Plan.

How quickly do Matthew Kiernan’s Clene Inc. (CLNN) stock options vest?

The options vest immediately upon grant, meaning there is no waiting or service period before they become exercisable. This immediate vesting is explicitly stated in the Form 4 footnote describing the option award.

Under which equity plan were Matthew Kiernan’s Clene Inc. (CLNN) options granted?

The option grant was made under the Clene Inc. Amended 2020 Stock Plan. This plan governs the terms of the equity award, including the number of shares covered, exercise price, and immediate vesting provisions disclosed in the insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiernan Matthew

(Last) (First) (Middle)

6550 SOUTH MILLROCK DRIVE

SUITE G50

(Street)

SALT LAKE CITY UT 84121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
stock option	$4.73	02/19/2026		A		2,755		(1)	02/18/2036	common stock	2,755	$0	2,755	D

Explanation of Responses:

1. This option was granted on February 19, 2026 as an option for 2,755 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

	/s/ Jerome T. Miraglia POA	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.